Clinical Trials Logo

Clinical Trial Summary

This is a Phase I trial to assess the safety and feasibility of administering pre-manufactured allogeneic T cells from healthy donors expressing CD19-targeting chimeric antigen receptors lacking expression of HLA class I, HLA class II molecules and endogenous TCR through CRISPR-mediated genome-editing of beta-2 microglobulin, CIITA and T cell receptor alpha chain, respectively. These cells are called PACE CART19 cells.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05037669
Study type Interventional
Source University of Pennsylvania
Status Not yet recruiting
Phase Phase 1
Start date January 2022
Completion date January 2038

See also
  Status Clinical Trial Phase
Recruiting NCT05009537 - Optical Genome Mapping in Hematological Malignancies
Terminated NCT01230788 - Rituximab for Patients With Relapsed Acute Lymphoblastic Leukemia N/A
Completed NCT00333190 - CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation N/A
Recruiting NCT02990572 - Amish/Mennonite Research Contact Registry
Completed NCT02631993 - Photochemotherapy and Graft-versus-leukemia in Acute-leukemia N/A
Completed NCT00863148 - Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL) Phase 2
Recruiting NCT04225676 - Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL) Phase 2
Recruiting NCT04601584 - GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL Phase 1/Phase 2
Not yet recruiting NCT05016947 - Venetoclax Plus Inotuzumab for B-ALL Phase 1
Recruiting NCT02861209 - Collaborative Network to Take Responsibility for Oral Anticancer Therapy N/A
Completed NCT01012492 - Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT Phase 2
Recruiting NCT04644016 - Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders Phase 2
Recruiting NCT03571321 - Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia Phase 1
Active, not recruiting NCT03154346 - Project Baseline Health Study
Terminated NCT01532635 - A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives Phase 2
Completed NCT01319864 - POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients Phase 1
Completed NCT00013533 - Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies Early Phase 1
Completed NCT01593696 - Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma Phase 1
Active, not recruiting NCT02776605 - Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia Phase 2
Completed NCT00539695 - Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD Phase 2